Current and emerging second-generation triptans in acute migraine therapy: A comparative review

Journal of Clinical Pharmacology

Volumn 40, Issue 7, 2000, Pages 687-700

  Deleu, D ^a   Hanssens, Y ^a  

^a SULTAN QABOOS UNIVERSITY HOSPITAL   (Oman)

Author keywords

[No Author keywords available]

Indexed keywords

ALMOTRIPTAN; ELETRIPTAN; FROVATRIPTAN; NARATRIPTAN; RIZATRIPTAN; SEROTONIN AGONIST; SUMATRIPTAN; ZOLMITRIPTAN;

COMPARATIVE STUDY; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; HUMAN; HYPERTENSION; HYPERTHERMIA; MENTAL DISEASE; MIGRAINE; REVIEW;

EID: 0033638471     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/00912700022009431     Document Type: Review

References (112)

1. Classification and diagnostic criteria for headache disorders, cranial neuralgias, and facial pain
2. Prevalence of migraine and other headaches in Hong Kong
3. Burden of migraine: A review of its socioeconomic impact
4. Epidemiology of headache in the general population: A prevalence study
5. A nationwide survey of migraine in France: Prevalence and clinical features in adults
6. A Canadian population survey on the clinical, epidemiologic and society impact of migraine and tension-type headache: Part II
7. Prevalence of migraine headache in the United States
8. Burden of migraine: Societal costs and therapeutic opportunities
9. The neurobiology of vascular head pain
10. Release of vasoactive peptides in the extracerebral circulation of man and the cat during activation of the trigeminovascular system
11. Neurogenic versus vascular mechanisms of sumatriptan and ergot alkaloids in migraine
12. 5-Hydroxytryptamine receptor subtypes and the pharmacology of migraine
13. Comparison of the vasoconstrictor effects of rizatriptan and sumatriptan in human isolated cranial arteries: Immunohistological demonstration of the involvement of 5-HT(1B)-receptors
14. 1 receptors in migraine pathophysiology and treatment
15. The functional activity of eletriptan and other 5-HT(1B/1D) agonists at the human recombinant 5-HT(1B) and 5-HT(1D) receptor
16. Pre-clinical pharmacology of zolmitriptan (Zomig(TM); formerly 311C90), a centrally and peripherally acting 5HT(1B/1D) agonist for migraine
17. Peripheral and central trigeminovascular activation in cat is blocked by the serotonin (5-HT)-1D receptor agonist 311C90
18. Evidence in man for a central effect of a 5-HT(1D) agonist, 311C90, from a study of the intensity dependence of the cortical evoked potential
19. The novel antimigraine agent rizatriptan has central antinociceptive effects against durally evoked responses
20. Inhibition of trigeminal neurones after intravenous administration of naratriptan through an action at 5-hydroxytryptamine (5-HT(1B/1D)) receptors
21. Differential effects of the 5-HT(1B/1D) receptor agonist naratriptan on trigeminal versus spinal nociceptive responses
22. Sumatriptan: Clinical pharmacokinetics
23. Symptomatic and prophylactic treatment of migraine: A critical reappraisal
24. Sumatriptan: An updated review of its use in migraine
25. Profiles of 5-HT(1B/1D) agonists in acute migraine with special reference to second generation agents
26. Drugs in development for migraine: Summary and table
27. Acute migraine therapy: The newer drugs
28. Antimigraine drugs
29. Guidelines for controlled trials of drugs in migraine: First edition
30. Zolmitriptan provides consistent migraine relief when used in the long-term
31. Coronary side-effect potential of current and prospective antimigraine drugs
32. The safety and tolerability of sumatriptan: An overview
33. Sumatriptan: A reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache
34. Sumatriptan in clinical practice: A 2-year review of 453 migraine patients
35. Cardiovascular safety of 5-HT(1B/1D) agonists: Is there a cause for concern?
36. 3 positron emission tomography
37. Rizatriptan vs sumatriptan in the acute treatment of migraine: A placebo-controlled, dose-ranging study
38. Tolerability profile of zolmitriptan (Zomig; 311C90), a novel dual central and peripherally acting 5HT1B/1D agonist. International clinical experience based on > 3000 subjects treated with zolmitriptan
39. Naratriptan is effective and well tolerated in the acute treatment of migraine: Results of a double-blind, placebo-controlled, crossover study
40. Eletriptan
41. Frovatriptan: Dose response studies
42. Pharmacological profile of almotriptan, a novel antimigraine agent
43. Antimigraine potential of almotriptan in animal models
44. Almotriptan
45. Effect of MAO-A inhibition on the pharmacokinetics of the novel antimigraine agent, almotriptan, in humans
46. First efficacy data on subcutaneous almotriptan, a novel 5-HT(1D) agonist
47. Efficacy data on oral almotriptan, a novel 5-HT(1D) agonist
48. Advantageous tolerability of almotriptan 12.5 mg compared with sumatriptan 100 mg
49. Characterisation of the 5-HT receptor binding profile of eletriptan and kinetics of [3H]eletriptan binding at human 5-HT(1B) and 5-HT(1D) receptors
50. Characterisation of the contractile activity of eletriptan at the canine vascular 5-HT(1B) receptor
51. Hemodynamic and coronary effects of intravenous eletriptan, a 5-HT(1B/1D) receptor agonist
52. The safety, tolerability, pharmacokinetics and pharmacodynamics of oral and intravenous eletriptan, a potent and selective '5-HT(1D)-like' receptor partial agonist
53. Human hepatocytes in primary culture predict lack of cytochrome P-450 3A4 induction by eletriptan in vivo
54. The absorption kinetics of eletriptan in migraineurs
55. The pharmacokinetics of eletriptan - A new oral agent for the acute treatment of migraine
56. The pharmacokinetic and pharmacodynamic interactions of oral eletriptan and propranolol in healthy volunteers
57. Eletriptan in acute migraine: A double-blind, placebo-controlled comparison to sumatriptan
58. Measures of rapid resolution of migraine symptoms and patient acceptance to treatment following eletriptan, sumatriptan and placebo
59. Efficacy, safety and tolerability of oral eletriptan versus placebo in the acute treatment of migraine: A phase III randomised study
60. Comparison of the efficacy of oral eletriptan and oral sumatriptan for the acute treatment of migraine: Combined analysis across three clinical trials
61. Migraine treatment: Regaining lost time. New eletriptan study results
62. Effects of the novel high-affinity 5-HT(1B/1D)-receptor ligand frovatriptan in human isolated basilar and coronary arteries
63. Effects of the novel antimigraine drug, SB 209509 (VML 251) in the coronary circulation
64. Pharmacokinetics of frovatriptan in young and elderly subjects
65. The effect of propranolol on the pharmacokinetic and safety profiles of frovatriptan
66. A preliminary study of VML251 (SB209509) a novel 5-HT(1B/1D) agonist for the treatment of acute migraine
67. A low-dose range-finding study of frovatriptan: A potent selective novel 5-HT(1B/1D) agonist for the treatment of acute migraine
68. Naratriptan: Biological profile in animal models relevant to migraine
69. Oral naratriptan tablets (2.5 mg-10 mg) exhibit dose-proportional pharmacokinetics
70. Early clinical experience with subcutaneous naratriptan in the acute treatment of migraine: A dose-ranging study
71. Clinical pharmacology and pharmacokinetics of naratriptan
72. Randomized, double-blind, placebo-controlled, comparison of oral naratriptan and oral sumatriptan in the acute treatment of migraine
73. Naratriptan is effective and well tolerated in the acute treatment of migraine: Results of a double-blind, placebo-controlled, parallel-group study
74. Naratriptan tablets 2.5 mg exhibit prolonged action and are well-tolerated in non-severe migraine attacks: Data from a comparator study with sumatriptan
75. Naratriptan 2.5 mg tablets have similar efficacy in the acute treatment of migraine as zolmitriptan 2.5 mg tablets, but exhibit a longer duration of action and are better tolerated: Results of a comparator study
76. Tolerability and efficacy of naratriptan tablets with long-term treatment (6 months)
77. Effects of subcutaneous naratriptan on systemic and pulmonary haemodynamics and coronary artery diameter in humans
78. Naratriptan compared with customary therapies enhances migraine patients' health-related quality of life
79. Pharmacokinetics and tolerability of oral rizatriptan in healthy male and female volunteers
80. Disposition and pharmacokinetics of the antimigraine drug, rizatriptan, in humans
81. Pharmacokinetics and food interaction of MK-462 in healthy males
82. The effects of moclobemide on the pharmacokinetics of the 5-HT(1B/1D) agonist rizatriptan in healthy volunteers
83. Lack of pharmacokinetic and pharmacodynamic interaction between rizatriptan and paroxetine
84. Double-blind, placebo-controlled, dose-finding study of rizatriptan (MK-462) in the acute treatment of migraine
85. A placebo-controlled, crossover study of rizatriptan in the treatment of multiple migraine attacks
86. Crossover comparison of rizatriptan 5 mg and 10 mg versus sumatriptan 25 mg and 50 mg in migraine
87. Oral rizatriptan versus oral sumatriptan: A direct comparative study in the acute treatment of migraine
88. Efficacy and safety of rizatriptan wafer for the acute treatment of migraine
89. Maxalt 10 mg shows beter work functioning than sumatriptan 50 mg
90. Validation of a migraine work and productivity loss questionnaire for use in migraine studies
91. Comparison of rizatriptan 10 mg vs. naratriptan 2.5 mg in migraine
92. Comparison of rizatriptan 10 mg versus zolmitriptan 2.5 mg in migraine
93. The clinical pharmacokinetics of zolmitriptan
94. Determination of human cytochrome P450 isoforms involved in the metabolism of zolmitriptan
95. Potential drug interactions with the novel antimigraine compound zolmitriptan (Zomig, 311C90)
96. The interaction between propranolol and the novel antimigraine agent zolmitriptan (311C90)
97. 2.5 mg 311C90 in the acute treatment of migraine: Efficacy and safety
98. Optimizing the dose of zolmitriptan (Zomig, 311C90) for the acute treatment of migraine: A multicenter, double-blind, placebo-controlled, dose range-finding study
99. Clinical efficacy and tolerability of 2.5 mg zolmitriptan for the acute treatment of migraine
100. Zolmitriptan, a 5-HT(1B/1D) receptor agonist for the acute oral treatment of migraine: A multicentre, dose-range finding study
101. 311C90 A new central and peripherally acting 5-HT(1D) receptor agonist in the acute oral treatment of migraine: A double blind, placebo-controlled, dose range finding study
102. The long-term tolerability and efficacy of oral zolmitriptan (Zomig, 311C90) in the acute treatment of migraine: An international study
103. The first comparison of the efficacy and safety of 311C90 and sumatriptan in the treatment of migraine
104. Impact of sumatriptan on clinic utilization and costs of care in migraineurs
105. Receptor specificity and trigemino-vascular inhibitory actions of a novel 5-HT(1B/1D) receptor partial agonist, 311C90 (zolmitriptan)
106. Human middle meningeal and coronary artery contraction to eletriptan and sumatriptan
107. Clozapine treatment of persistent paroxysmal dyskinesia associated with concomitant paroxetine and sumatriptan use
108. Drug interaction studies and metabolic enzyme characterisation with zolmitriptan (Zomig)